189 related articles for article (PubMed ID: 24787737)
21. New insights in the treatment by levofloxacin.
File TM
Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
[TBL] [Abstract][Full Text] [Related]
22. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Sydnor TA; Kopp EJ; Anthony KE; LoCoco JM; Kim SS; Fowler CL
Ann Allergy Asthma Immunol; 1998 Apr; 80(4):357-62. PubMed ID: 9564988
[TBL] [Abstract][Full Text] [Related]
23. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
24. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of the Japanese Respiratory Society guidelines for community pneumonia: a retrospective analysis of community-acquired pneumonia between 2000 and 2002 in a general hospital.
Motomura K; Masaki H; Terada M; Onizuka T; Furumoto A; Asoh N; Oishi K; Nagatake T
Respirology; 2005 Mar; 10(2):208-14. PubMed ID: 15823187
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
27. Nationwide survey on the 2005 Guidelines for the Management of Community-Acquired Adult Pneumonia: validation of differentiation between bacterial pneumonia and atypical pneumonia.
Watanabe A; Goto H; Kohno S; Matsushima T; Abe S; Aoki N; Shimokata K; Mikasa K; Niki Y
Respir Investig; 2012 Mar; 50(1):23-32. PubMed ID: 22554856
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore.
Chiang WC; Teoh OH; Chong CY; Goh A; Tang JP; Chay OM
Respirology; 2007 Mar; 12(2):254-61. PubMed ID: 17298459
[TBL] [Abstract][Full Text] [Related]
29. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
[TBL] [Abstract][Full Text] [Related]
30. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
[TBL] [Abstract][Full Text] [Related]
31. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
32. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia.
Grenier C; Pépin J; Nault V; Howson J; Fournier X; Poirier MS; Cabana J; Craig C; Beaudoin M; Valiquette L
J Antimicrob Chemother; 2011 Jul; 66(7):1617-24. PubMed ID: 21586592
[TBL] [Abstract][Full Text] [Related]
33. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
Shindo Y; Ito R; Kobayashi D; Ando M; Ichikawa M; Shiraki A; Goto Y; Fukui Y; Iwaki M; Okumura J; Yamaguchi I; Yagi T; Tanikawa Y; Sugino Y; Shindoh J; Ogasawara T; Nomura F; Saka H; Yamamoto M; Taniguchi H; Suzuki R; Saito H; Kawamura T; Hasegawa Y
Am J Respir Crit Care Med; 2013 Oct; 188(8):985-95. PubMed ID: 23855620
[TBL] [Abstract][Full Text] [Related]
35. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
Melo-Cristino J; Fernandes ML; Serrano N;
Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
[TBL] [Abstract][Full Text] [Related]
36. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
37. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
[TBL] [Abstract][Full Text] [Related]
38. Leave the levofloxacin? A case report of levofloxacin-induced psychosis.
Steuber H; Williams D; Rech MA
Am J Emerg Med; 2018 Aug; 36(8):1528.e1-1528.e2. PubMed ID: 29779676
[TBL] [Abstract][Full Text] [Related]
39. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
[TBL] [Abstract][Full Text] [Related]
40. [Prospects of Levofloxacin Use in Therapy of Patients with Bronchopulmonary Diseases or Skin and Soft Tissue Pyo-Inflammatory Lesions].
Sokolova VI; Sychev DA; Babarina MB; Zaikov DA
Antibiot Khimioter; 2014; 59(11-12):35-9. PubMed ID: 26448992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
